The Technical Analyst
Select Language :
Prelude Therapeutics [PRLD]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Prelude Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

Prelude Therapeutics is listed at the  Exchange

-0.63% $4.74

America/New_York / 28 mar 2024 @ 16:00


Prelude Therapeutics: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 321.23 mill
EPS: -2.02
P/E: -2.35
Earnings Date: May 05, 2024
SharesOutstanding: 67.77 mill
Avg Daily Volume: 0.0741 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Sell
DE: Neutral
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.35 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.40x
Company: PE -2.35 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$0.139
(-97.06%) $-4.60
Date: 2024-03-28
Expected Trading Range (DAY)

$ 4.32 - 5.12

( +/- 8.52%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-01 Lim Bryant David Buy 150 000 Employee Stock Option (right to buy)
2024-03-01 Scherle Peggy Buy 150 000 Employee Stock Option (right to buy)
2024-03-01 Combs Andrew Buy 150 000 Employee Stock Option (right to buy)
2024-03-01 Chardonnet Laurent Buy 150 000 Employee Stock Option (right to buy)
2024-03-01 Huang Jane Buy 175 000 Employee Stock Option (right to buy)
INSIDER POWER
99.44
Last 98 transactions
Buy: 26 933 589 | Sell: 357 744

Forecast: 16:00 - $4.72

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $4.72
Forecast 2: 16:00 - $4.72
Forecast 3: 16:00 - $4.72
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $4.74 (-0.63% )
Volume 0.0161 mill
Avg. Vol. 0.0741 mill
% of Avg. Vol 21.75 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Prelude Therapeutics Incorporat

Last 12 Months

Last 12 months chart data with high, low, open and close for Prelude Therapeutics Incorporat

RSI

Intraday RSI14 chart for Prelude Therapeutics Incorporat

Last 10 Buy & Sell Signals For PRLD

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Prelude Therapeutics Incorporat

PRLD

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Last 10 Buy Signals

Date Signal @
FUMOUSDMar 28 - 18:5410 001
ALPHUSDMar 28 - 18:542.71
HNTUSDMar 28 - 18:47$6.19
WBTUSDMar 28 - 18:438.37
TRXUSDMar 28 - 18:39$0.120
XMRUSDMar 28 - 18:34$135.06
IONUSDMar 28 - 18:23454.85
APE18876USDMar 28 - 18:212.02
DAOUSDMar 28 - 18:19$1.823
TONUSDMar 28 - 18:134.88

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.